Correlation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zeng, Wenjiao ^a,c   Van Den Berg, Anke ^a   Huitema, Sippie ^a   Gouw, Annette S H ^a   Molema, Grietje ^b   De Jong, Koert P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CYCLOOXYGENASE 2; MESSENGER RNA; MICRORNA 101; MICRORNA 16; MICRORNA 21; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; MICRORNA; MIRN101 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; PTGS2 PROTEIN, HUMAN;

ADULT; ANGIOPOIETIN 1 GENE; ANGIOPOIETIN 2 GENE; ANGIOPOIETIN RECEPTOR GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DISEASE ASSOCIATION; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; VASCULOTROPIN A GENE; VASCULOTROPIN RECEPTOR 1 GENE; VASCULOTROPIN RECEPTOR 2 GENE; WESTERN BLOTTING; AGED; GENETICS; IN VITRO STUDY; LIVER TUMOR; METABOLISM; MIDDLE AGED;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; FEMALE; HUMANS; IN VITRO TECHNIQUES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 84899753865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095826     Document Type: Article

References (41)

1. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56: 908-943.
2. El Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460-468. (Pubitemid 38182303)
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638. (Pubitemid 36459468)
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140. (Pubitemid 34747534)
5. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43: S99-S112.
6. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759. (Pubitemid 41400849)
7. Hu KQ (2003) Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukot Essent Fatty Acids 69: 329-337.
8. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073. (Pubitemid 28418937)
9. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747. (Pubitemid 43983297)
10. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32: 28-44.
11. Giordano S, Columbano A (2013) MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57: 840-847.
12. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, et al. (2011) MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 6: e19139.
13. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, et al. (2012) MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 7: e29671.
14. Olivieri F, Spazzafumo L, Santini G, Lazzarini R, Albertini MC, et al. (2012) Age-related differences in the expression of circulating microRNAs: MiR-21 as a new circulating marker of inflammaging. Mech Ageing Dev 133: 675-685.
15. Schetter AJ, Nguyen GH, Bowman ED, Mathe EA, Yuen ST, et al. (2009) Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 15: 5878-5887.
16. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39: 493-506.
17. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, et al. (2011) Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 6: e26971.
18. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, et al. (2009) MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315: 1439-1447.
19. He XP, Shao Y, Li XL, Xu W, Chen GS, et al. (2012) Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212.
20. Agra Andrieu N, Motino O, Mayoral R, Llorente Izquierdo C, Fernandez-Alvarez A, et al. (2012) Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells. PLoS One 7: e50935.
21. Gouw AS, Zeng W, Buiskool M, Platteel I, van den Heuvel MC, et al. (2010) Molecular characterization of the vascular features of focal nodular hyperplasia and hepatocellular adenoma: A role for angiopoietin-1. Hepatology 52: 540-549.
22. Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, et al. (2009) Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia 11: 167-176.
23. Pradet-Balade B, Boulme F, Beug H, Mullner EW, Garcia-Sanz JA (2001) Translation control: Bridging the gap between genomics and proteomics? Trends Biochem Sci 26: 225-229. (Pubitemid 32289240)
24. Tait CR, Jones PF (2004) Angiopoietins in tumours: The angiogenic switch. J Pathol 204: 1-10. (Pubitemid 39214476)
25. Hao Y, Gu X, Zhao Y, Greene S, Sha W, et al. (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 4: 1073-1083.
26. Okayama H, Schetter AJ, Harris CC (2012) MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig Dis 30 Suppl 2: 9-15.
27. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658. (Pubitemid 47187346)
28. Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, et al. (2012) Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 7: e51655.
29. Zeng W, Gouw AS, van den Heuvel MC, Molema G, Poppema S, et al. (2010) Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. Ann Surg Oncol 17: 1564-1571.
30. Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, et al. (2008) The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 48: 1517-1527.
31. Kumarswamy R, Volkmann I, Thum T (2011) Regulation and function of miRNA-21 in health and disease. RNA Biol 8: 706-713.
32. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, et al. (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727-1736.
33. Mata J, Marguerat S, Bahler J (2005) Post-transcriptional control of gene expression: A genome-wide perspective. Trends Biochem Sci 30: 506-514. (Pubitemid 41206506)
34. Gygi SP, Rochon Y, Franza BR, Aebersold R (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730. (Pubitemid 29098230)
35. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, et al. (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1: 304-313.
36. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, et al. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467. (Pubitemid 350233144)
37. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15: 31-33.
38. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46: 108-125. (Pubitemid 46661865)
39. Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, et al. (2008) Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med.
40. Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, et al. (2002) Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol 17: 1110-1116.
41. Breinig M, Rieker R, Eiteneuer E, Wertenbruch T, Haugg AM, et al. (2008) Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer 122: 547-557. (Pubitemid 350308945)